EN CH
x
x
Search
Ginkgo Health
Our Research On Ginkgo Biloba Jingelai ®️ Ginkgolide Injection Ginkgolide Dropping Pills CDMO Service International Standard Production Base
  • Good News! Baiyu Pharmaceutical Has Been Listed As One Of The Top 100 Traditional Chinese Medicine Enterprises In China For Six Consecutive Years
    Good News! Baiyu Pharmaceutical Has Been Listed As One Of The Top 100 Traditional Chinese Medicine Enterprises In China For Six Consecutive Years
    On June 25th, The Highly Anticipated 2023 China Pharmaceutical Industry Top 100 Series List Was Officially Released At The Mi Net 2024 Mi Si Conference. The List Is Divided Into Five Major Series, Including The "China Chemical Pharmaceutical Enterprise TOP100 Ranking" And The "China Traditional Chinese Medicine Enterprise TOP100 Ranking".
    06-28-2024
  • Ginkgolide Injection Received Authoritative Recommendation For Chinese Cerebrovascular Disease Management Guidelines In 2023
    Ginkgolide Injection Received Authoritative Recommendation For Chinese Cerebrovascular Disease Management Guidelines In 2023
    Beijing, China, Cambridge, Massachusetts, USA, And Basel, Switzerland& December 22, 2023& Mdash; BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), A Global Biotechnology Company, Announced Today That The US Food And Drug Administration (FDA) Has Approved BRUKINSA® (Zebutinib, Chinese Trade Name: Baiyueze®) Updated The Instruction Manual To Include Its Comparison With Yike® Ibrutinib Is Used For The Treatment Of
    06-02-2024
  • Ginkgolide Injection Was Listed As A Recommended Medication In The "Guidelines For The Prevention And Treatment Of Stroke In China" In 2021
    Ginkgolide Injection Was Listed As A Recommended Medication In The "Guidelines For The Prevention And Treatment Of Stroke In China" In 2021
    Beijing, China, Cambridge, Massachusetts, USA, And Basel, Switzerland& December 22, 2023& Mdash; BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), A Global Biotechnology Company, Announced Today That The US Food And Drug Administration (FDA) Has Approved BRUKINSA® (Zebutinib, Chinese Trade Name: Baiyueze®) Updated The Instruction Manual To Include Its Comparison With Yike® Ibrutinib Is Used For The Treatment Of
    06-02-2024
  • Jingelai ®️ Ginkgo Bilobalide Total Dropping Pills Have Entered Phase III Clinical Trials
    Jingelai ®️ Ginkgo Bilobalide Total Dropping Pills Have Entered Phase III Clinical Trials
    Beijing, China, Cambridge, Massachusetts, USA, And Basel, Switzerland& December 22, 2023& Mdash; BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), A Global Biotechnology Company, Announced Today That The US Food And Drug Administration (FDA) Has Approved BRUKINSA® (Zebutinib, Chinese Trade Name: Baiyueze®) Updated The Instruction Manual To Include Its Comparison With Yike® Ibrutinib Is Used For The Treatment Of
    06-02-2024
Guestbook
Guestbook
Top
Top